• Corpus ID: 10138474

Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands.

@article{Tedford1999DevelopmentOT,
  title={Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands.},
  author={Clark E. Tedford and James G. Phillips and Rosilyn Gregory and Gary Pawlowski and Leena Fadnis and M. A. Khan and S. M. Ali and Michael Handley and Stephen L. Yates},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={1999},
  volume={289 2},
  pages={
          1160-8
        }
}
Previously, a novel series of 1H-4-substituted imidazole compounds were described as potent and selective histamine (HA) H3 receptor ligands (Yates et al., 1999). The present studies extend the structure-activity relationships for optimal HA H3 receptor affinity and central nervous system penetration by incorporation of a conformationally restricted cyclopropane nucleus. Moreover, the current studies extend our understanding of ligand-receptor interactions at the HA H3 receptor with the… 

Figures and Tables from this paper

Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.

The present studies demonstrate the development of novel HA H3-selective ligands, and lend support for the use of such agents in the treatment of disorders associated with cognitive or attentional deficits.

Cherry-picked ligands at histamine receptor subtypes

Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist.

International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors

The H3R is an autoreceptor and heteroreceptor providing negative feedback on histaminergic and inhibition on other neurons, a block of these actions promotes waking and the development of anti-inflammatory drugs is anticipated.

References

SHOWING 1-10 OF 35 REFERENCES

Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.

The present studies demonstrate the development of novel HA H3-selective ligands, and lend support for the use of such agents in the treatment of disorders associated with cognitive or attentional deficits.

Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists.

New, potent, and selective histamine H3 receptor antagonists have been synthesized by employing the use of (1) an appropriately positioned nonpolar acetylene spacer group, (2) either a two-carbon

Identification of two H3-histamine receptor subtypes.

The distinction between H3A and H3B receptor subtypes, the former a high affinity and the latter a low affinity thioperamide site, draws support from published in vitro data.

High antagonist potency of GT-2227 and GT-2331, new histamine H3 receptor antagonists, in two functional models.

Histamine homologues discriminating between two functional H3 receptor assays. Evidence for H3 receptor heterogeneity?.

The homologue of histamine with five methylene groups is a more potent H3 receptor antagonist in the guinea pig jejunum than the other homologue tested, and the propylene, butylene and pentylene homologues can discriminate between the two functional H3 receptors models in the Guinea pigJejunum and mouse brain.

Histamine H3 receptors modulate the release of [3H]‐acetylcholine from slices of rat entorhinal cortex: evidence for the possible existence of H3 receptor subtypes

The effects of the selective H3 receptor agonist, (R)‐α‐methylhistamine (RAMH), and a number of H3 receptors antagonists, including the selective compound thioperamide, on the potassium‐stimulated release of tritium are examined.

Pharmacological characterization of GT-2016, a non-thiourea-containing histamine H3 receptor antagonist: in vitro and in vivo studies.

The results show that GT-2016 crosses the blood-brain barrier, binds to H3 receptors and increases the release of histamine in the cerebral cortex, consistent with blockade of presynaptic H3 autoreceptors.